Prime Medicine, Inc.
PRMEHealthcare|Biotechnology|US
$4.65
+0.20 (+4.49%)
Tangible Book / Share
$0.22
Cash / Share
$0.54
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07748403 A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) | Wilson Disease, Wilson's Disease | P1P2 | Recruiting | 42 | Open-label | PM577a |
| NCT07226622 Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial | Wilson Disease | Active | 30 | — | — | |
| NCT07887347 A Study of the Safety and Efficacy of Prime Editing (PM647a) in Participants With Alpha-1 Antitrypsin Deficiency | Alpha-1 Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency-associated Lung Disease | P1P2 | Not Yet Recruiting | 54 | Open-label | PM647a |
| NCT06559176 A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) | Chronic Granulomatous Disease, Granulomatous Disease, Chronic | P1P2 | By Invite | 12 | Open-label | PM359 |